 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > IDEC Pharmaceuticals Corporation
 |
IDEC Pharmaceuticals Corporation |
 |
 |
 |
NEWS FROM THE WIRES |
 |
IDEC says its FDA accepts review of Zevalin drug Aug 02 2001 05:21 AM PDT
IDEC says regulators to review Zevalin Sept. 11 Jul 23 2001 06:27 AM PDT
RPT-Idec Pharmaceuticals Q2 profit rises 71 percent Jul 19 2001 01:17 PM PDT
Idec Pharmaceuticals Q2 profit rises 71 percent Jul 19 2001 01:07 PM PDT
INTERVIEW-Taisho bets future on prescription drugs Jul 18 2001 01:06 AM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
Late Market Movers: Dow Inches Up, Nasdaq Slips
Nov 27 2000 02:52 PM PST
PROFILE |
 |
IDEC Pharmaceuticals develops treatments for cancer and autoimmune and inflammatory diseases. The company's first FDA-approved product, the best-selling Rituxan, treats non-Hodgkin's lymphoma (NHL). Delivered intravenously, Rituxan is a monoclonal antibody used in place of chemotherapy or radiation treatment. Biotech giant Genentech manufactures Rituxan and is involved in its development and marketing. Through licensing agreements, Hoffmann-La Roche sells Rituxan outside the US and Canada, except in Japan, where Zenyaku Kogyo markets the drug. Lead drug candidate ZEVALIN also targets NHL. IDEC Pharmaceuticals has several more products, including autoimmune candidates, in its pipeline.
COMPETITION |
 |
Agouron Pharmaceuticals, Inc. (dossier)
AstraZeneca PLC (AZN)
Immunex Corporation (IMNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 154.70
1-Yr. Sales Growth: 31.1%
Employees: 493
Revenue per employee: $313,793.10
KEY PEOPLE |
 |
William H. Rastetter
CEO
Phillip M. Schneider
CFO
CONTACT INFO |
 |
3030 Callan Rd.
San Diego, CA 92121
US
Phone: 858-431-8500
Fax: 858-431-8750
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |